+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Hodgkin's Lymphoma Drugs Market 2019-2023 - Product Image

Global Hodgkin's Lymphoma Drugs Market 2019-2023

  • ID: 4758167
  • Report
  • Region: Global
  • 113 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Merck & Co., Inc.
  • Pfizer Inc.
  • Seattle Genetics, Inc.
  • MORE
Hodgkin's lymphoma is one of the most curable forms of lymphoma, with a patient survival rate of more than five years. The high unmet need for novel and innovative alternative treatment approaches. In addition, the introduction of target molecular hallmarks of this disease, including the aberrant phenotype of cancer cells, deregulated cancer pathways, and immune escape mechanisms. With an increased understanding of the fundamental biology of Hodgkin's lymphoma, companies have been able to develop drugs that are effective in treating the disease. This is expected to drive the market growth during the forecast period. The analysts have predicted that the hodgkin’s lymphoma drugs market will register a CAGR of close to 16% by 2023.

Market Overview

Development of novel pipeline drugs

The increase in the prevalence of Hodgkin's lymphoma has led to a high unmet need for a strong pipeline of disease-modifying drugs. R&D activities are resulting in the availability of new drugs for the treatment of Hodgkin's lymphoma.

Treatment of Hodgkin's lymphoma patients with conjoint conditions

The treatment of Hodgkin’s lymphoma has generally been successful and well-tolerated by patients. However, there are challenges associated with the treatment of patients that have Hodgkin's lymphoma with conjoint conditions, such as cardiac diseases, HIV infection, and pregnancy. Hodgkin's lymphoma is more common in patients with HIV. The presence of HIV in patients with Hodgkin's lymphoma can have a negative impact on treatment tolerance and prognosis.

For the detailed list of factors that will drive and challenge the growth of the Hodgkin’s lymphoma drugs market during the 2019-2023, view this report.

Competitive Landscape

The market appears to be moderately concentrated and with the presence of limited vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Merck & Co., Inc.
  • Pfizer Inc.
  • Seattle Genetics, Inc.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 07: MARKET SEGMENTATION BY TYPE
  • Market segmentation by type
  • Comparison by type
  • Targeted therapy - Market size and forecast 2018-2023
  • Chemotherapy - Market size and forecast 2018-2023
  • Market opportunity by type
PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 12: MARKET TRENDS
  • Market trends
PART 13: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 14: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • ONO PHARMACEUTICAL CO., LTD.
  • Pfizer Inc.
  • Seattle Genetics, Inc.
PART 15: APPENDIX
  • Research methodology
  • List of abbreviations
List of Exhibits
Exhibit 01: Global oncology therapeutics market
Exhibit 02: Segments of global oncology therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline drugs in late-stage clinical trials
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Type - Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Targeted therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Targeted therapy - Year-over-year growth 2019-2023 (%)
Exhibit 22: Chemotherapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Chemotherapy - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 32: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 34: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 36: Key leading countries
Exhibit 37: Market opportunity
Exhibit 38: Impact of drivers and challenges
Exhibit 39: Vendor landscape
Exhibit 40: Landscape disruption
Exhibit 41: Vendors covered
Exhibit 42: Vendor classification
Exhibit 43: Market positioning of vendors
Exhibit 44: Bristol-Myers Squibb Company - Vendor overview
Exhibit 45: Bristol-Myers Squibb Company - Business segments
Exhibit 46: Bristol-Myers Squibb Company - Organizational developments
Exhibit 47: Bristol-Myers Squibb Company - Geographic focus
Exhibit 48: Bristol-Myers Squibb Company - Key offerings
Exhibit 49: Merck & Co., Inc. - Vendor overview
Exhibit 50: Merck & Co., Inc. - Business segments
Exhibit 51: Merck & Co., Inc. - Organizational developments
Exhibit 52: Merck & Co., Inc. - Geographic focus
Exhibit 53: Merck & Co., Inc. - Segment focus
Exhibit 54: Merck & Co., Inc. - Key offerings
Exhibit 55: ONO PHARMACEUTICAL CO., LTD. - Vendor overview
Exhibit 56: ONO PHARMACEUTICAL CO., LTD. - Business segments
Exhibit 57: ONO PHARMACEUTICAL CO., LTD. - Organizational developments
Exhibit 58: ONO PHARMACEUTICAL CO., LTD. - Geographic focus
Exhibit 59: ONO PHARMACEUTICAL CO., LTD. - Key offerings
Exhibit 60: Pfizer Inc. - Vendor overview
Exhibit 61: Pfizer Inc. - Business segments
Exhibit 62: Pfizer Inc. - Organizational developments
Exhibit 63: Pfizer Inc. - Geographic focus
Exhibit 64: Pfizer Inc. - Segment focus
Exhibit 65: Pfizer Inc. - Key offerings
Exhibit 66: Seattle Genetics, Inc. - Vendor overview
Exhibit 67: Seattle Genetics, Inc. - Business segments
Exhibit 68: Seattle Genetics, Inc. - Organizational developments
Exhibit 69: Seattle Genetics, Inc. - Geographic focus
Exhibit 70: Seattle Genetics, Inc. - Key offerings
Exhibit 71: Validation techniques employed for market sizing
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Merck & Co., Inc.
  • Pfizer Inc.
  • Seattle Genetics, Inc.
  • MORE
Global Hodgkin’s Lymphoma Drugs Market 2019-2023

The analyst recognizes the following companies as the key players in the global Hodgkin’s lymphoma drugs market: Bristol-Myers Squibb Company, Merck & Co., Inc., ONO PHARMACEUTICAL CO., LTD., Pfizer Inc., Seattle Genetics, Inc..

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the increasing use if immunotherapy and transplantation to treat Hodgkin’s lymphoma.”

According to the report, one of the major drivers for this market is the availability of patient assistance programs increases patient access and adherence to drugs. This is expected to drive the growth of the market during our forecast period.

Further, the report states that one of the major factors hindering the growth of this market is the high cost of treatment may pose as a challenge to the market.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • ONO PHARMACEUTICAL CO., LTD.
  • Pfizer Inc.
  • Seattle Genetics, Inc.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4758167
Adroll
adroll